Bayer, Onyx Pharmaceuticals Announce FDA Priority Review Designation of Nexavar

Bayer HealthCare (OTC: BAYRY ) and Onyx Pharmaceuticals (NASDAQ: ONXX ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation to the supplemental New Drug Application (sNDA) for the oral multi-kinase inhibitor Nexavar® (sorafenib) tablets under evaluation for the treatment of locally